I-Mab Biopharma Opens US Office in Rockville, Maryland

Rockville MD—JUN 2018 — I-Mab Biopharma, announced the opening of its US office in Rockville, Maryland. The grand opening ceremony was honored by the presence of representatives from biotech and pharma industries and prominent members of local Chinese-American community, including Ms. Lily Qi, Assistant Chief Administrative Officer, Montgomery County Office of the County Executive and Mr. Zheng Yang, Attache of Science and Technology from Embassy of the People’s Republic of China in Washington DC.

The US Office is located in the innovative biotech hub on east coast and it will be an important center for I-Mab to leverage the resources and develop stronger connection with partners worldwide.

I-Mab Biopharma US Office

“The establishment of I-Mab US office demonstrates that Rockville Maryland is the right place for life science companies to develop more commercial opportunities, and I-Mab is an essential part of the harmonious relations in Rockville Maryland. We are looking forward to providing more opportunities to life science companies such as I-Mab.” Ms. Qi said as she presented a Certificate of Recognition promulgated by the Montgomery County Executive Office.

I-Mab was awarded a Certificate of Recognition

“Today’s opening ceremony is a milestone for I-Mab. As an innovation-driven company, I-Mab believes this expansion will allow our company to become a global player in immuno-oncology and immunology for innovative and transformational medicines.” Head of Research and Development and CMO, Dr. Joan Shen said.

“Rockville Maryland has a unique blend of resources of biotech, academic and regulatory agencies. Our office here will focus on the clinical development of I-Mab assets and look for collaboration and partnership opportunities in US.” said Dr. Claire Xu, Head of US office.

About I-Mab

At I-Mab, we strive to be a global biopharmaceutical company based in China to deliver innovative, transformational medicines for patients around the world.
Through internal R&D and in-licensing, we have established “Global Portfolio” and “China Portfolio” to develop first-in-class and best-in-class products in the therapeutic areas of immune-oncology and immuno-inflammation.
We are on a rapid development pace towards a fully integrated company. Since 2015, the first phase for discovery, I-Mab has developed 7 to 8 first-in-class or best-in-class candidates up to date within 3 years. We are currently at the second phase for development, planning to conduct multiple clinical trials in both China and the US in 2018 and 2019. Moving to the next stage, we expect to launch the first product in 2020, with expectation of releasing one new product onto the market yearly.

US Office Contact Info:
Tel:301-670-2800 ex 1990